Heparin-induced thrombocytopenia in a nonthrombocytopenic patient with toxic epidermal necrolysis causing fatal outcome: Is hit still a hit?

Journal of Burn Care and Research

Volumn 30, Issue 4, 2009, Pages 747-751

  Busche, Marc Nicolai ^a   Peters, Tina ^a   Knobloch, Karsten ^a   Vogt, Peter Maria ^a   Rennekampff, Hans Oliver ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; CARBAMAZEPINE; CATECHOLAMINE; CORTICOSTEROID; HEPARIN; IMMUNOGLOBULIN; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DISORDER; BLISTER; BODY SURFACE; BURN; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MALE; OUTCOME ASSESSMENT; POPULATION; SCREENING; SEROLOGY; THROMBECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED DISORDER; FATALITY;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; EPIDERMAL NECROLYSIS, TOXIC; FATAL OUTCOME; HEPARIN; HUMANS; MALE; THROMBOCYTOPENIA;

EID: 69249231150     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3181ac05bf     Document Type: Article

References (28)

1. Everett BM, Yeh R, Foo SY, et al. Prevalence of heparin/ platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 2007;83:592-597
2. Stribling WK, Slaughter TF, Houle TT, Sane DC. Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J 2007;153:900-906
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1336
4. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524
5. Scott JR, Klein MB, Gernsheimer T, Honari S, Gibbons J, Gibran NS. Arterial and venous complications of heparin-induced thrombocytopenia in burn patients. J Burn Care Res 2007;28:71-75
6. Phelan BK. Heparin-associated thrombosis without throm-bocytopenia. Ann Intern Med 1983;99:637-638
7. Hach-Wunderle V, Kainer K, Krug B, Müller-Berghaus G, Pötzsch B. Heparin-associated thrombosis despite normal platelet counts. Lancet 1994;344:469-470
8. Klement D, Rammos S, Kries R, Kirschke W, Kniemeyer HW, Greinacher A. Heparin as a cause of thrombus progression. Eur J Pediatr 1996;155:11-14.
9. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530-2536
10. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106: 629-635
11. Kappers-Klunne MC, Boon DM, Hop WC, et al. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebro-vascular diseases. Br J Haematol 1997;96:442-446
12. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005;153:241-253
13. Niedermayr M, Schramm W, Kamolz L, et al. Antithrombin deficiency and its relationship to severe burns. Burns 2007; 33:173-178
14. Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chon-droitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotech 2008;26:669-675
15. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358: 2457-2467
16. Beiderlinden M, Treschan TA, Gorlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007;41:749-754
17. Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005;25:1736-1745
18. Koster A, Hentschel T, Groman T, et al. Argatroban antico-agulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg 2007;133:1376-1377
19. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149-153
20. Majumdar S, Mockenhaupt M, Roujeau J, Townshend A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev 2002;CD001435.
21. Parrillo SJ. Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Allergy Asthma Rep 2007;7:243-247
22. Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30- day myocardial infarction after acute coronary ischemic syndromes. Circulation 2003;107:2307-2312
23. Bennett-Guerrero E, Slaughter TF, White WD, et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005; 130:1567-1572
24. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.
25. Francis JL. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost 2004;30:359-368
26. Warkentin TE, Greinacher A. Heparin-induced thrombocy- topenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:311S-337S.
27. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocyto-penia. Blood 2005;106:2921-2922
28. Warkentin TE. Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies-distinguishing "signal" from "noise". Thromb Haemost 2008;100:523-524